All News

Older woman

Polymyalgia rheumatica: more than just steroids at ACR22

d David Liew, FRACP

After decades of having little else proven apart from glucocorticosteroids with which to treat polymyalgia rheumatica (PMR), evidence for steroid-sparing options has grown in recent years, and this crescendo is set to continue at ACR Convergence 2022 in Philadelphia, PA.

Read Article
female woman symbol

Does BASDAI work for women?

d Rachel Tate, DO

When it comes to Spondyloarthritis we have numerous disease activity measures and much debate regarding best practices. When it comes to determining which to use in clinic, discrepancies occur. Do our activity measures truly represent disease? Are there some measures best suited to different populations? Does BASDAI work for women?

Read Article
acr_session2.jpeg

Industry Abstract Previews of ACR 2022

d Jack Cush, MD

The pharmaceutical companies have will showcase their featured clinical trials and abstracts at ACR 2022.  These are their best studies for you to review and evaluate as part of your to-do list.

Read Article
RheumNow Podcast square

Prelude to a Meeting (ACR22) (11.11.2022)

d Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com and looks forward to highlight sessions in the next few days at ACR Convergence 2022.

Read Article
“Expert rheumatologist opinion remains the gold standard!” – Dr. J Scher on diagnosis of #axSpa I would like to think this quote applies to everything, not just to axSpa (-my own opinion) #ACRreview #ACR22 @rheumnow https://t.co/zpwQwXA8o2
TheDaoIndex KDAO2011 ( View Tweet)
Withdrawing IL17i will more likely cause a relapse, but pts will respond when reintroduced -Dr Scher #PsA @rheumnow #acr22 #acrreview https://t.co/FvWVuQGJda
TheDaoIndex KDAO2011 ( View Tweet)
Dr. Sheila Reyes is back and covering #ACR22 as a RheumNow reporter. Follow @RHEUMarampa from real-time conference coverage! https://t.co/MeA2RggI9S
Dr. John Cush RheumNow ( View Tweet)
Sialadenosis is a mimic of #sjogren - it related to fatty infiltration/metabolic syndrome. Correct underlying issue and pts will improve - Dr S McCoy @rheumnow #acrreview #acr22 https://t.co/bZPj1LmERs
TheDaoIndex KDAO2011 ( View Tweet)
Wonderful slide by Dr. Sarah McCoy on #Sjogrens #ACR22 @RheumNow Broad differential for these patients when they present in clinic: 📍Ask about: 🚬 habits 💊 meds 🍬 🩻history: #diabetes, past radiation exposure 🦠 infection (#HIV, #HCV) 🩸 #vitamin deficiency https://t.co/6Qo23lWBs4
Catherine Sims, MD DrCassySims ( View Tweet)
Mark your calendars! RheumNow Live is back on 3/18-3/19 in Dallas, Texas. Register now! https://t.co/xQkdHjEVgS https://t.co/moyJhNHgHk

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Coldiron (thru case examples) shares how the MSF works in providing medical care to pts in areas of conflict or crisis & how #climate change has also impacted health, including #Mentalhealth #ACR22 @RheumNow @rheumarhyme https://t.co/gFuX4sL0WA
sheila RHEUMarampa ( View Tweet)
50 yo hispanic male +MDA5 Ab w/ synovitis, skin lesions, neg ANA, normal CK, aldolase, +MDA5 Ab, Skin biopsy show changes c/w dermatomyositis. Failed MTX/MMF, no insurance. What is MDA5's role? Does race play a factor in Rx response? What is your next step? @rheumnow #ACR22 https://t.co/tGy2BH6y45
TheDaoIndex KDAO2011 ( View Tweet)
Dr. R Puligari: 55 yo female w/arthritis, rash, DOE, fever, weight loss, CT abnormal +MDA5 dermatomyositis: Rx RTX, IV steroids, CYP, TAC and Ofev. Disease progressed; IVIG,steroids, PLEX added w/benefits. 6 months later had CMV retinitis. What to do next? #ACR22 @rheumnow https://t.co/A1m8HMtCob
TheDaoIndex KDAO2011 ( View Tweet)
#ClinicalPearl #Methotrexate is recommended for Rx in all EXCEPT…#ACR22 @RheumNow

Janet Pope Janetbirdope ( View Tweet)

Dr. M Tikly share #rheum challenges & solutions in South Africa: 👉⬆️training to gen. practitioners & nurses, 👉estab outreach clinics 👉lobby local government/political groups 👉use of off-label drugs 👉engage pharma: free meds/clinical trials #ACR22 #GlobalHealth @rheumnow https://t.co/BX2qXk1usN
TheDaoIndex KDAO2011 ( View Tweet)
Dr. Tikly discusses the solutions to drug access challenges in South Africa in both state and private sectors 👇 🔸Off label use, buyouts, price⬇️, advocacy... Highly relatable because these are similar challenges we face in the PH @rheumarhyme @doktora_ging #ACR22 @rheumnow https://t.co/ajshylgtIE
sheila RHEUMarampa ( View Tweet)
Finally we're starting to get therapies for polymyalgia rheumatica! The best of PMR therapeutics coming up at #ACR22 (and catch it all @RheumNow): https://t.co/lUPICA3Mim
David Liew drdavidliew ( View Tweet)
#ACR22 Presents New Data on JIA Clinical Remission with Combo DMARDSs New research being presented at #ACR22, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with combo DMARDSs. https://t.co/qmfnEvDedA https://t.co/VhkYlZJG3s

Links:

Dr. John Cush RheumNow ( View Tweet)
Update: axSpA Recommendations https://t.co/KaBb11WLQD https://t.co/8kIaa0WuvM

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 78 824 adults shows Prevalence of Cannabis use was significantly higher during the pandemic vs before the pandemic in states where it is legalized (but not increase in nonlegal states) esp in adults 18 to 29 and 30 to 54 years https://t.co/ZZzCl7dstj https://t.co/qbQLPhI6I8

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×